SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE is expected to benefit from a potential increase in hospital payments for their custom implants, along with strong financial performance and growth, expansion plans, successful sales model, and partnership with Smith & Nephew contributing to revenue growth. Despite potential challenges, the company is rated as a buy and has exceeded expectations in sales and EBITDA, with further growth expected with the launch of new products and expansion of their customer base.

SI-BONE is showing promising growth potential with a record number of active surgeons and potential reimbursement tailwinds in the future, but their current rev & GM guidance still seem conservative considering the SNN partnership and potential opportunities in interventional and trauma procedures. Despite pressure on ASPs, strong performance from Granite implants and continued strength in the SI Joint business may offset this. However, with a small step down in GM and a decline in ASPs, their profitability outlook may not be as strong as expected. The recent launch of INTRA Ti and potential expansion into ASCs may drive future growth, but it remains to be seen if it will be enough to justify the current stock price and valuation.